New shot could help kidney transplant patients fight rejection

NCT ID NCT06503731

Ongoing Disease control Sponsor: argenx Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 02, 2026 · Updated 2 times

Summary

This study tests a drug called efgartigimod, given as a shot under the skin, for people who have antibody-mediated rejection after a kidney transplant. The trial includes 30 adults who received a kidney at least 6 months ago and have signs of rejection. Participants will receive either the drug or a placebo, along with their usual anti-rejection medications, for 48 weeks, followed by 24 weeks of observation. The goal is to see if the drug is safe and can help control rejection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Efgartigimod PH20 SC (a drug given by injection under the skin)
What this could lead to: If it works, this could offer a new way to treat antibody-mediated rejection in kidney transplant patients, potentially helping to preserve kidney function and reduce the need for stronger treatments.
What could go wrong: This is an early Phase 2 trial with only 30 participants, so results may not apply to everyone. The drug is tested alongside standard immunosuppression, and its long-term safety and effectiveness are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIBODY MEDIATED REJECTION

Contacts and locations

Locations

Allgemeines Krankenhaus der Stadt Wien (AKH Wien) - Medizinischer Universitätscampus

Vienna, 1090, Austria
Cedars-Sinai Medical Center

Los Angeles, California, 90048, United States
Centre Hospitalier Universitaire (CHU) de Bordeaux - Hôpital Pellegrin

Bordeaux, 33076, France
Centre Hospitalier Universitaire (CHU) de Grenoble Alpes - Hôpital Michallon

La Tronche, 38700, France
Centre Hospitalier Universitaire (CHU) de Toulouse - Hôpital de Rangueil

Toulouse, 31059, France
Charité - Universitätsmedizin Berlin

Berlin, 13353, Germany
Duke University Hospital

Durham, North Carolina, 27705, United States
Hospital Del Mar

Barcelona, 08003, Spain
Hospital Universitario Miguel Servet

Zaragoza, 50009, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario de Bellvitge

Barcelona, 08907, Spain
Institut klinicke a experimentalni mediciny (IKEM)

Prague, 140-21, Czechia
London Health Sciences Centre

London, N6A 5A5, Canada
The Ohio State University Wexner Medical Center

Columbus, Ohio, 43210, United States
Universitaetsklinikum Carl Gustav Carus Dresden

Dresden, 01307, Germany
Universitair Ziekenhuis (UZ) Gent

Ghent, 9000, Belgium
Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg

Leuven, 3000, Belgium
University of Alabama at Birmingham (UAB) Hospital

Birmingham, Alabama, 35233, United States
University of Chicago Medical Center

Chicago, Illinois, 60615, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Washington Medical Center

Seattle, Washington, 98195, United States
Universitätsklinikum Hamburg-Eppendorf

Hamburg, 20246, Germany
Virginia Commonwealth University (VCU) Medical Center Hume-Lee Transplant Center

Richmond, Virginia, 23298, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.